Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068912 · ClinicalTrials.gov registry record · Phase 2
Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza
A Phase 2 study of Influenza, sponsored by MDVI.
- Completed
- Registry status
- Phase 2
- Development phase
- 530
- Enrollment target
- 20
- Study locations
NCT01068912 is a Phase 2 study of Influenza that has completed, run by MDVI. The registered enrollment target is 530 participants, below the 36,801-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT01068912, a Phase 2 study of Influenza, has completed, sponsored by MDVI.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 530 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of two doses of favipiravir in adult patients with uncomplicated influenza.
Conditions Studied
Interventions
- DRUG Placebo comparator
- DRUG Favipiravir
Study Locations (20)
Alabama
- #065 - Birmingham
- #156 - Huntsville
- #151 - Mobile
- #155 - Scottsboro
- #173 - Toney
- #161 - Tuscumbia
California
- #059 - Anaheim
- #179 - Anaheim
- #032 - Chino
- #154 - Cypress
- #004 - Garden Grove
- #144 - Long Beach
Arizona
- #089 - Chandler
- #018 - Green Valley
- #110 - Mesa
- #105 - Phoenix
- #188 - Tucson
Arkansas
- #107 - Jonesboro
- #019 - North Little Rock
- #140 - Searcy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01068912
The ClinicalTrials.gov registry entry for NCT01068912 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 530 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,801-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The listed sponsor is MDVI, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Placebo comparator is the first listed.
NCT01068912 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alabama, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT01068912 about?
NCT01068912 is a clinical study titled "Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza". This is a Phase 2, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of two doses of favipiravir in adult patients with uncomplicated influenza.
What is the current status of trial NCT01068912?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 530 participants. The study started on 2010-02. Estimated completion is 2012-05.
What conditions does trial NCT01068912 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT01068912?
The interventions under investigation include: Placebo comparator (DRUG), Favipiravir (DRUG).
Who is sponsoring clinical trial NCT01068912?
This trial is sponsored by MDVI, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01068912 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
RECRUITING · Phase 2
-
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
RECRUITING · Phase 2
-
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
RECRUITING · Phase 2
-
Systems Investigation of Vaccine Responses in Aging and Frailty
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
RECRUITING · Phase 2
-
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.